阿片类镇痛药减少研究(OARS)试点:双盲随机多中心试验。

IF 2.2 Q2 DENTISTRY, ORAL SURGERY & MEDICINE
JDR Clinical & Translational Research Pub Date : 2024-01-01 Epub Date: 2023-01-20 DOI:10.1177/23800844221144031
C A Feldman, J Fredericks-Younger, P J Desjardins, H Malmstrom, M Miloro, G Warburton, B Ward, V Ziccardi, D H Fine, P Greenberg, T Andrews, P B Matheson, S-E Lu
{"title":"阿片类镇痛药减少研究(OARS)试点:双盲随机多中心试验。","authors":"C A Feldman, J Fredericks-Younger, P J Desjardins, H Malmstrom, M Miloro, G Warburton, B Ward, V Ziccardi, D H Fine, P Greenberg, T Andrews, P B Matheson, S-E Lu","doi":"10.1177/23800844221144031","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>With addiction rates and opioid deaths increasing, health care providers are obligated to help stem the opioid crisis. As limited studies examine the comparative effectiveness of fixed-dose combination nonopioid analgesia to opioid-containing analgesia, a comparative effectiveness study was planned and refined by conducting a pilot study.</p><p><strong>Methods: </strong>The Opioid Analgesic Reduction Study (OARS) pilot, a stratified, randomized, multisite, double-blind clinical trial, was designed to test technology and procedures to be used in the full OARS trial. Participants engaged in the full protocol, enabling the collection of OARS outcome data. Eligible participants reporting to 1 of 5 sites for partial or full bony impacted mandibular third molar extraction were stratified by biologic sex and randomized to 1 of 2 treatment groups, OPIOID or NONOPIOID. OPIOID participants were provided 20 doses of hydrocodone 5 mg/acetaminophen 300 mg. NONOPIOID participants were provided 20 doses of ibuprofen 400 mg/acetaminophen 500 mg. OARS outcomes data, including pain experience, adverse effects, sleep quality, pain interference, overall satisfaction, and remaining opioid tablets available for diversion, were collected via surveys, electronic medication bottles, eDiary, and activity/sleep monitor.</p><p><strong>Results: </strong>Fifty-three participants were randomized with 50 completing the OARS pilot protocol. Across all outcome pain domains, in all but 1 time period, NONOPIOID was better in managing pain than OPIOID (<i>P</i> < 0.05 level). Other outcomes suggest less pain interference, less adverse events, better sleep quality, better overall satisfaction, and fewer opioid-containing tablets available for diversion.</p><p><strong>Discussion: </strong>Results suggest patients requiring impacted mandibular third molar extraction would benefit from fixed-dose combination nonopioid analgesia.</p><p><strong>Knowledge transfer statement: </strong>Study results suggest fixed-dose nonopioid combination ibuprofen 400 mg/acetaminophen 500 mg is superior to opioid-containing analgesic (hydrocodone 5 mg/acetaminophen 500 mg). This knowledge should inform surgeons and patients in the selection of postsurgical analgesia.</p>","PeriodicalId":14783,"journal":{"name":"JDR Clinical & Translational Research","volume":" ","pages":"72-84"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10850879/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Opioid Analgesic Reduction Study (OARS) Pilot: A Double-Blind Randomized Multicenter Trial.\",\"authors\":\"C A Feldman, J Fredericks-Younger, P J Desjardins, H Malmstrom, M Miloro, G Warburton, B Ward, V Ziccardi, D H Fine, P Greenberg, T Andrews, P B Matheson, S-E Lu\",\"doi\":\"10.1177/23800844221144031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>With addiction rates and opioid deaths increasing, health care providers are obligated to help stem the opioid crisis. As limited studies examine the comparative effectiveness of fixed-dose combination nonopioid analgesia to opioid-containing analgesia, a comparative effectiveness study was planned and refined by conducting a pilot study.</p><p><strong>Methods: </strong>The Opioid Analgesic Reduction Study (OARS) pilot, a stratified, randomized, multisite, double-blind clinical trial, was designed to test technology and procedures to be used in the full OARS trial. Participants engaged in the full protocol, enabling the collection of OARS outcome data. Eligible participants reporting to 1 of 5 sites for partial or full bony impacted mandibular third molar extraction were stratified by biologic sex and randomized to 1 of 2 treatment groups, OPIOID or NONOPIOID. OPIOID participants were provided 20 doses of hydrocodone 5 mg/acetaminophen 300 mg. NONOPIOID participants were provided 20 doses of ibuprofen 400 mg/acetaminophen 500 mg. OARS outcomes data, including pain experience, adverse effects, sleep quality, pain interference, overall satisfaction, and remaining opioid tablets available for diversion, were collected via surveys, electronic medication bottles, eDiary, and activity/sleep monitor.</p><p><strong>Results: </strong>Fifty-three participants were randomized with 50 completing the OARS pilot protocol. Across all outcome pain domains, in all but 1 time period, NONOPIOID was better in managing pain than OPIOID (<i>P</i> < 0.05 level). Other outcomes suggest less pain interference, less adverse events, better sleep quality, better overall satisfaction, and fewer opioid-containing tablets available for diversion.</p><p><strong>Discussion: </strong>Results suggest patients requiring impacted mandibular third molar extraction would benefit from fixed-dose combination nonopioid analgesia.</p><p><strong>Knowledge transfer statement: </strong>Study results suggest fixed-dose nonopioid combination ibuprofen 400 mg/acetaminophen 500 mg is superior to opioid-containing analgesic (hydrocodone 5 mg/acetaminophen 500 mg). This knowledge should inform surgeons and patients in the selection of postsurgical analgesia.</p>\",\"PeriodicalId\":14783,\"journal\":{\"name\":\"JDR Clinical & Translational Research\",\"volume\":\" \",\"pages\":\"72-84\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10850879/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JDR Clinical & Translational Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/23800844221144031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JDR Clinical & Translational Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23800844221144031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

背景:随着成瘾率和阿片类药物致死率的上升,医疗服务提供者有责任帮助遏制阿片类药物危机。由于研究固定剂量非阿片类镇痛药与含阿片类镇痛药的比较效果的研究有限,因此计划开展一项比较效果研究,并通过开展试点研究对其进行完善:减少阿片类镇痛药研究(OARS)试验是一项分层、随机、多地点、双盲临床试验,旨在测试将在 OARS 全面试验中使用的技术和程序。参与者参与完整的试验方案,从而能够收集到 OARS 的结果数据。符合条件的参试者在 5 个地点中的 1 个地点进行下颌第三磨牙部分或全部骨性影响拔除术,并按生物性别进行分层,随机分为 OPIOID 或 NONOPIOID 两组。OPIOID 组的参与者服用 20 次氢可酮 5 毫克/对乙酰氨基酚 300 毫克。NONOPIOID 参与者接受 20 次布洛芬 400 毫克/对乙酰氨基酚 500 毫克的治疗。通过问卷调查、电子药瓶、电子日记和活动/睡眠监测仪收集 OARS 结果数据,包括疼痛体验、不良反应、睡眠质量、疼痛干扰、总体满意度和剩余的阿片类药物片剂可供转用:53 名参与者被随机分配,其中 50 人完成了 OARS 试点方案。在所有疼痛结果方面,除一个时间段外,NONOPIOID 在控制疼痛方面的效果均优于 OPIOID(P < 0.05)。其他结果表明,疼痛干扰更少、不良事件更少、睡眠质量更好、总体满意度更高、可转用的含阿片药片更少:讨论:研究结果表明,需要拔除下颌第三磨牙的患者将受益于固定剂量非阿片类药物联合镇痛:研究结果表明,固定剂量非阿片类镇痛药布洛芬 400 毫克/对乙酰氨基酚 500 毫克优于含阿片类镇痛药(氢可酮 5 毫克/对乙酰氨基酚 500 毫克)。这一知识应为外科医生和患者选择术后镇痛提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Opioid Analgesic Reduction Study (OARS) Pilot: A Double-Blind Randomized Multicenter Trial.

Background: With addiction rates and opioid deaths increasing, health care providers are obligated to help stem the opioid crisis. As limited studies examine the comparative effectiveness of fixed-dose combination nonopioid analgesia to opioid-containing analgesia, a comparative effectiveness study was planned and refined by conducting a pilot study.

Methods: The Opioid Analgesic Reduction Study (OARS) pilot, a stratified, randomized, multisite, double-blind clinical trial, was designed to test technology and procedures to be used in the full OARS trial. Participants engaged in the full protocol, enabling the collection of OARS outcome data. Eligible participants reporting to 1 of 5 sites for partial or full bony impacted mandibular third molar extraction were stratified by biologic sex and randomized to 1 of 2 treatment groups, OPIOID or NONOPIOID. OPIOID participants were provided 20 doses of hydrocodone 5 mg/acetaminophen 300 mg. NONOPIOID participants were provided 20 doses of ibuprofen 400 mg/acetaminophen 500 mg. OARS outcomes data, including pain experience, adverse effects, sleep quality, pain interference, overall satisfaction, and remaining opioid tablets available for diversion, were collected via surveys, electronic medication bottles, eDiary, and activity/sleep monitor.

Results: Fifty-three participants were randomized with 50 completing the OARS pilot protocol. Across all outcome pain domains, in all but 1 time period, NONOPIOID was better in managing pain than OPIOID (P < 0.05 level). Other outcomes suggest less pain interference, less adverse events, better sleep quality, better overall satisfaction, and fewer opioid-containing tablets available for diversion.

Discussion: Results suggest patients requiring impacted mandibular third molar extraction would benefit from fixed-dose combination nonopioid analgesia.

Knowledge transfer statement: Study results suggest fixed-dose nonopioid combination ibuprofen 400 mg/acetaminophen 500 mg is superior to opioid-containing analgesic (hydrocodone 5 mg/acetaminophen 500 mg). This knowledge should inform surgeons and patients in the selection of postsurgical analgesia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JDR Clinical & Translational Research
JDR Clinical & Translational Research DENTISTRY, ORAL SURGERY & MEDICINE-
CiteScore
6.20
自引率
6.70%
发文量
45
期刊介绍: JDR Clinical & Translational Research seeks to publish the highest quality research articles on clinical and translational research including all of the dental specialties and implantology. Examples include behavioral sciences, cariology, oral & pharyngeal cancer, disease diagnostics, evidence based health care delivery, human genetics, health services research, periodontal diseases, oral medicine, radiology, and pathology. The JDR Clinical & Translational Research expands on its research content by including high-impact health care and global oral health policy statements and systematic reviews of clinical concepts affecting clinical practice. Unique to the JDR Clinical & Translational Research are advances in clinical and translational medicine articles created to focus on research with an immediate potential to affect clinical therapy outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信